首页> 外文期刊>JAMA: the Journal of the American Medical Association >Retinoblastoma therapy delivers power of chemotherapy with surgical precision.
【24h】

Retinoblastoma therapy delivers power of chemotherapy with surgical precision.

机译:视网膜母细胞瘤疗法可提供具有手术精确性的化学疗法。

获取原文
获取原文并翻译 | 示例
           

摘要

THE PAST CENTURY HAS SEEN GREAT strides in the treatment of reti-noblastoma, with more than 95% of US patients now being cured of this rare childhood malignancy. Building on this success, ophthalmologists have sought to minimize the adverse effects from radiation and systemic chemotherapy, hoping not only to cure the disease but also to save the eye and preserve vision. Radiation can achieve this end, but it also can give rise to secondary cancers. And while systemic chemotherapy-which replaced radiation in the 1990s as first-line treatment for retinoblastoma-is effective in shrinking tumors, it has many adverse effects, including hearing impairment, development of second cancers, and long-term fertility issues. Systemic chemotherapy also does not fully eradicate the tumor, necessitating additional focal techniques such as laser therapy or cryotherapy that require the patient to undergo numerous examinations, procedures, and treatments.
机译:过去的世纪在视网膜母细胞瘤的治疗方面取得了长足的进步,目前有95%以上的美国患者已经治愈了这种罕见的儿童恶性肿瘤。在此成功的基础上,眼科医生已寻求将放射线和全身化学疗法的不良影响减至最小,不仅希望治愈该疾病,还希望挽救眼睛和保持视力。辐射可以达到这个目的,但它也可以引起继发性癌症。全身化疗虽然在1990年代取代了放射线,成为视网膜母细胞瘤的一线治疗方法,但对缩小肿瘤有效,但它却有许多不利影响,包括听力障碍,第二种癌症的发展以及长期生育问题。全身化学疗法也不能完全根除肿瘤,因此需要额外的聚焦技术,例如激光疗法或冷冻疗法,需要患者进行大量检查,程序和治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号